TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22581487

Group type: EXPERIMENTAL
Intervention: Soap-opera-themed, Thai-language EE video
Number of subjects: 0

Group type: COMPARATOR
Intervention: Print handout (brochure)
Number of subjects: 0
Study: 20372089

Group type: EXPERIMENTAL
Intervention: Live attenuated varicella-zoster virus (VZV) vaccine, two doses 12 weeks apart
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 19060996

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (40 minutes on a cycle-ergometer at 60% of reserve heart rate)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 50
Study: 15916369

Group type: EXPERIMENTAL
Intervention: EHF‐IR therapy on biologically active points
Number of subjects: 130

Group type: COMPARATOR
Intervention: EHF therapy alone
Number of subjects: 130

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 130
Study: 12105828

Group type: EXPERIMENTAL
Intervention: Erythromycin (250 mg intravenous bolus infusion, 20 minutes before endoscopy)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: COMPARATOR
Intervention: Erythromycin and Placebo
Number of subjects: 105
Study: 9545623

Group type: EXPERIMENTAL
Intervention: Standard hypocaloric diet + ephedrine (2 x 25 mg) + caffeine (2 x 200 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Standard hypocaloric diet + ephedrine (2 x 25 mg) + caffeine (2 x 200 mg) + yohimbine (2 x 5 mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard hypocaloric diet
Number of subjects: 27
Study: 7704057

Group type: EXPERIMENTAL
Intervention: Patient navigator intervention
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Non-navigated patients
Number of subjects: 1136

Group type: COMPARATOR
Intervention: Patients with suspicious findings
Number of subjects: 1136
Study: 2692698

Group type: EXPERIMENTAL
Intervention: Upright positions (squatting, kneeling, sitting or standing)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Conventional positions (semi-recumbent and lateral)
Number of subjects: 151
Study: 20919

Group type: EXPERIMENTAL
Intervention: Salbutamol 0.5%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Salbutamol 0.25%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rimiterol 0.5%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rimiterol 0.5% (second dose 2h after first)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rimiterol 0.5% (first dose)
Number of subjects: 0
Study: 30481998

Group type: EXPERIMENTAL
Intervention: 33 °C
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: 36 °C
Number of subjects: 938

Group type: COMPARATOR
Intervention: Place of residence
Number of subjects: 938
Study: 28219815

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26289742

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FP/SAL) 100/50 mcg
Number of subjects: 339

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 100 mcg
Number of subjects: 339
Study: 23835328

Group type: EXPERIMENTAL
Intervention: Genetic risk score based on 46 variants
Number of subjects: 5850
Study: 21878658

Group type: EXPERIMENTAL
Intervention: Documentation software
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Documentation software plus a timed reminder
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Documentation software, a timed reminder, and an electronic decision support prompt
Number of subjects: 531

Group type: COMPARATOR
Intervention: Pharmacies without documentation software
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Overall interventions
Number of subjects: 531
Study: 19017312

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) treatment
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 17026651

Group type: EXPERIMENTAL
Intervention: Poria cocos (PoCo) applied in three concentrations in base cream DAC during the induction period of ICD.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poria cocos (PoCo) applied once a day for 5 days after the induction of ICD.
Number of subjects: 0
Study: 15615131

Group type: EXPERIMENTAL
Intervention: Anterior repositioning splint
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Canine‐protected splint
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 18
Study: 10954340

Group type: EXPERIMENTAL
Intervention: Activated charcoal (25 g in 200 ml water)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Gastric lavage (10x200 ml)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (200 ml water)
Number of subjects: 9
Study: 9310272

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) infusion (120 microg/day) for 7 consecutive days
Number of subjects: 8
Study: 7841611

Group type: COMPARATOR
Intervention: Human milk
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: WHF 3
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: SCHF
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: WCHF
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: WHF 1 and WHF 2
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Plasma amino acid pattern
Number of subjects: 107
Study: 3360973

Group type: EXPERIMENTAL
Intervention: 7432-S 25 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 7432-S 50 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 7432-S 100 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 7432-S 200 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 7432-S 100 mg twice daily for 2 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 7432-S 200 mg twice daily for 1 week
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 7432-S (all doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31106840

Group type: EXPERIMENTAL
Intervention: Pre-treatment with antiplatelet drugs (acetylsalicylic acid 15 mg/kg, clopidogrel 11 mg/kg, ticagrelor 27 mg/kg, prasugrel 1.5 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-treatment with antiplatelet drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no antiplatelet treatment)
Number of subjects: 0
Study: 29753703

Group type: EXPERIMENTAL
Intervention: NGR-hTNF 0·8 μg/m2 intravenously plus best investigator choice (n=200)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo plus best investigator choice (n=200)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: NGR-hTNF 0·8 μg/m2 intravenously
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 28192892

Group type: EXPERIMENTAL
Intervention: Nefopam (IV 120 mg continuous infusion for 48 hours)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (placebo, same infusion for 48 hours)
Number of subjects: 69
Study: 26922845

Group type: EXPERIMENTAL
Intervention: Pilates program
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Trunk strengthening exercise program
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study: 23246444

Group type: EXPERIMENTAL
Intervention: Passive heat maintenance jacket (PHM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (normal training attire)
Number of subjects: 20
Study: 21318930

Group type: EXPERIMENTAL
Intervention: Tailored web-based intervention
Number of subjects: 171

Group type: COMPARATOR
Intervention: Non-tailored intervention group
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 171
Study: 19439517

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) training
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Fitness group (cardiovascular, resistance, balance and stretching exercises)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 220
Study: 17119469

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamins and minerals (120 mg vitamin C, 30 mg vitamin E, 6 mg beta-carotene, 100 microg selenium, 20 mg zinc)
Number of subjects: 12741

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12741
Study: 15599146

Group type: EXPERIMENTAL
Intervention: Immediate individualized training using a computer-controlled patient simulator
Number of subjects: 50

Group type: COMPARATOR
Intervention: Delayed individualized training using a computer-controlled patient simulator
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Direct observation of interns in actual initial airway events
Number of subjects: 50
Study: 11741553

Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 399

Group type: COMPARATOR
Intervention: Stenting after balloon predilatation
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Patients treated later in the study
Number of subjects: 399
Study: 9401096

Group type: EXPERIMENTAL
Intervention: Somatosensory evoked potentials (SEPs) with median nerve stimulation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Auditory evoked potentials (AEPs) with binaural stimulation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Heart rate (HR)
Number of subjects: 36
Study: 7957149

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Scopolamine 0.3 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of Atenolol and Scopolamine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 12
Study: 2955007

Group type: EXPERIMENTAL
Intervention: Biperiden (intravenous administration)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 28
Study: 31994405

Group type: EXPERIMENTAL
Intervention: Cycle ergometer training group (10-minute session, twice a day)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Standard physiotherapy protocol (10-minute session)
Number of subjects: 228
Study: 29653208

Group type: EXPERIMENTAL
Intervention: Ixekizumab 120 mg, then 80 mg subcutaneously once every 4 weeks
Number of subjects: 93
Study: 27470183

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) patch applied for 24 hours after surgery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo patch applied for 24 hours after surgery
Number of subjects: 200
Study: 25261199

Group type: EXPERIMENTAL
Intervention: 10 IU/kg prophylaxis
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 40 IU/kg prophylaxis
Number of subjects: 74

Group type: COMPARATOR
Intervention: On-demand treatment
Number of subjects: 74
Study: 22412081

Group type: COMPARATOR
Intervention: ACSM model
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Periodized model
Number of subjects: 32
Study: 20852375

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid capsule, 1 g 3 times a day for 2 months
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo for 2 months
Number of subjects: 75
Study: 18285430

Group type: EXPERIMENTAL
Intervention: Exercise intervention (twice-weekly classes and once-weekly independent exercise for three months)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (monitored monthly, management unchanged)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 15736727

Group type: EXPERIMENTAL
Intervention: Mindfulness-based Stress Reduction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study: 12796584

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Surgicel
Number of subjects: 48

Group type: COMPARATOR
Intervention: Pressure
Number of subjects: 48
Study: 11194702

Group type: COMPARATOR
Intervention: Telephone-based intervention targeting lifestyle-related health risks in seven areas (back care, cholesterol control, eating habits, exercise and activities, stress management, tobacco use, weight control) with 3-5 contacts over 1 year.
Number of subjects: 607

Group type: COMPARATOR
Intervention: Telephone-based intervention targeting lifestyle-related health risks.
Number of subjects: 607

Group type: COMPARATOR
Intervention: Telephone-based intervention.
Number of subjects: 607
Study: 9004342

Group type: EXPERIMENTAL
Intervention: Clonidine (0.15 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Yohimbine (15 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8300869

Group type: EXPERIMENTAL
Intervention: Subtle and obvious MCMI items
Number of subjects: 241
Study: 3088219

Group type: EXPERIMENTAL
Intervention: Cisplatin (120 mg/m2) plus Vindesine
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cisplatin (60 mg/m2) plus Vindesine plus Mitomycin C
Number of subjects: 124

Group type: COMPARATOR
Intervention: Vindesine alone
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cisplatin and Vindesine
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cisplatin, Vindesine, and Mitomycin C
Number of subjects: 124

Group type: COMPARATOR
Intervention: Vindesine
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Cisplatin plus Vindesine
Number of subjects: 124
Study: 28786494

Group type: EXPERIMENTAL
Intervention: DBBM and L‐PRF mixture (test)
Number of subjects: 13

Group type: COMPARATOR
Intervention: DBBM alone (control)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 13
Study: 27409478

Group type: EXPERIMENTAL
Intervention: Aflibercept or ranibizumab intravitreal injections
Number of subjects: 24
Study: 24988072

Group type: EXPERIMENTAL
Intervention: Higher levels of mindfulness
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Lower levels of mindfulness
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Higher numbers of previous episodes of depression
Number of subjects: 274
Study: 22746353

Group type: EXPERIMENTAL
Intervention: FlexTouch (FT)
Number of subjects: 90
Study: 20434886

Group type: EXPERIMENTAL
Intervention: Diabetes Awareness and Rehabilitation Training (DART)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Usual Care Plus Information (UCI)
Number of subjects: 52
Study: 18388877

Group type: EXPERIMENTAL
Intervention: 600 mg gemfibrozil
Number of subjects: 10
Study: 16186596

Group type: EXPERIMENTAL
Intervention: Allogeneic stem-cell transplantation (alloSCT)
Number of subjects: 472

Group type: COMPARATOR
Intervention: No donor group (autologous SCT)
Number of subjects: 472
Study: 12814477

Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 174

Group type: COMPARATOR
Intervention: Noninduction therapy
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: T-cell depleting antibody induction
Number of subjects: 174
Study: 11420887

Group type: EXPERIMENTAL
Intervention: Slow-release theophylline
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8855815

Group type: EXPERIMENTAL
Intervention: Estradiol 0.1 mg/day transdermally
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1516394

Group type: EXPERIMENTAL
Intervention: Continuous infusion of furosemide following a single loading dose (LDCI)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intermittent intravenous administration of furosemide (IA)
Number of subjects: 9
Study: 3841410

Group type: EXPERIMENTAL
Intervention: 0.5 mg atropine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 5 mg pirenzepine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 50 mg pirenzepine twice daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: 17.5 mg benzilonium bromide twice daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: 35 mg benzilonium bromide twice daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: 0.6 mg L-hyoscyamine twice daily
Number of subjects: 32
Study: 31013264

Group type: EXPERIMENTAL
Intervention: 0.014-inch floppy guidewire
Number of subjects: 124

Group type: COMPARATOR
Intervention: 0.019-inch straight guidewire
Number of subjects: 124
Study: 29923955

Group type: EXPERIMENTAL
Intervention: 1.5 mL/kg lipid infusion (lipid group)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Saline infusion (control group)
Number of subjects: 12
Study: 27861379

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 25517548

Group type: EXPERIMENTAL
Intervention: Active lidocaine hydrochloride 2% (Dynexan)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 29
Study: 23115195

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active-Control Group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness Training (MT) with greatest amount of practice
Number of subjects: 0
Study: 19562349

Group type: EXPERIMENTAL
Intervention: 5% glucose water (group B)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Distilled water (group A)
Number of subjects: 38
Study: 19087704

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Methotrexate (MTX) treatment
Number of subjects: 60
Study: 15944166

Group type: EXPERIMENTAL
Intervention: Interactive toy distraction
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Passive movie distraction
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 88
Study: 11828229

Group type: EXPERIMENTAL
Intervention: Pathology Group (PG)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 18
Study: 9915371

Group type: EXPERIMENTAL
Intervention: Low frequency stimulation (20 Hz)
Number of subjects: 24

Group type: COMPARATOR
Intervention: High frequency stimulation (100 Hz)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Stimulation at 1/15 duty cycle
Number of subjects: 24
Study: 9345448

Group type: EXPERIMENTAL
Intervention: BRB‐N tests administered every 60 days for 120 days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: PASAT results
Number of subjects: 19
Study: 2264720

Group type: EXPERIMENTAL
Intervention: Cubital nerve block with prilocaine (15 ml of 10 mg/ml)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Haematoma block
Number of subjects: 35
Study: 84901

Group type: EXPERIMENTAL
Intervention: Human leucocyte interferon
Number of subjects: 4
Study: 31778659

Group type: EXPERIMENTAL
Intervention: Voluntary aerobic exercise and upper extremity repetitive task practice (VE+UERTP, n=15)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Forced aerobic exercise and upper extremity repetitive task practice (FE+UERTP, n=16)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nonaerobic control group (control, n=13)
Number of subjects: 44
Study: 30704414

Group type: EXPERIMENTAL
Intervention: Retrograde application of bone marrow aspirate concentrate (BMAC) via coronary sinus
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard heart failure therapy
Number of subjects: 40
Study: 29960294

Group type: EXPERIMENTAL
Intervention: Feet reflexology (RG)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Segmental massage (SMG)
Number of subjects: 48
Study: 25530510

Group type: EXPERIMENTAL
Intervention: 2-day immobilization with the knee in 20° of flexion postoperatively (group A, n=18)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 1-week immobilization (group B, n=17)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 2-week immobilization (group C, n=16)
Number of subjects: 51
Study: 23623915

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 0
Study: 21218272

Group type: EXPERIMENTAL
Intervention: TTM-tailored feedback intervention delivered via an interactive multimedia computer system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TTM-tailored feedback intervention
Number of subjects: 0
Study: 19764439

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl analgesia (0.7 microg x kg(‐1) x hr(‐1) during operation, decreased to 0.5 microg x kg(‐1) x hr(‐1) next morning)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epidural analgesia (0.4 microg x kg(‐1) x hr(‐1) fentanyl and 5 ml x hr(‐1) 1% mepivacaine during operation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl analgesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 30
Study: 17805134

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no fibrin glue)
Number of subjects: 200
Study: 15061241

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (CE) (0.625 mg/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 44
Study: 11523886

Group type: EXPERIMENTAL
Intervention: FOTI
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard clinical examination
Number of subjects: 29
Study: 9551707

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg every morning for 2 weeks
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg every morning with cimetidine 300 mg four times a day for 2 weeks
Number of subjects: 12
Study: 8156961

Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 38
Study: 2899586

Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of netilmicin and metronidazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 1105116

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo-acupuncture
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atrovent (parasympatholytic drug)
Number of subjects: 12
Study: 30785361

Group type: EXPERIMENTAL
Intervention: Favorable comments (n = 43)
Number of subjects: 881

Group type: COMPARATOR
Intervention: Unfavorable comments (n = 34)
Number of subjects: 881

Group type: COMPARATOR
Intervention: No comments (n = 0)
Number of subjects: 881
Study: 29110741

Group type: COMPARATOR
Intervention: Control flatbreads (C)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15 % CPF with 2 % GG (GG2)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 15 % CPF with 4 % GG (GG4)
Number of subjects: 12